Summary & Overview
HCPCS J0594: Injection, busulfan, 1 mg
HCPCS Level II code J0594 designates an injection of busulfan measured per 1 mg. Busulfan is an alkylating chemotherapeutic agent used in conditioning regimens and certain oncology protocols, making accurate coding essential for drug reimbursement, inventory tracking, and clinical reporting nationwide. This code matters nationally because it standardizes how payers and providers document busulfan dosing across outpatient infusion centers, hospital clinics, and oncology practices.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for busulfan administration, common billing practices, and payer coverage considerations. The publication highlights typical sites of service and service line classification for injectable chemotherapy and presents benchmarks where available.
The report does not prescribe clinical or billing actions. It provides reference material on HCPCS Level II code J0594, explains what the code represents, identifies primary payers in scope, and outlines what sections will address reimbursement patterns, coding guidance, and related policy updates when such data are available.
Billing Code Overview
HCPCS Level II code J0594 represents an injection of busulfan, 1 mg. This billing code denotes administration of the chemotherapeutic agent busulfan in a measured unit of 1 milligram. The service type is drug administration / injectable chemotherapy, typically delivered as part of oncology or hematology treatment regimens. The typical site of service for procedures billed with this code is hospital outpatient departments, infusion centers, and specialized oncology clinics where intravenous or other parenteral chemotherapy is provided.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 45-year-old patient with relapsed acute myeloid leukemia is scheduled to receive busulfan as part of a myeloablative conditioning regimen prior to allogeneic hematopoietic stem cell transplantation. The medication is supplied and billed as J0594 (injection, busulfan, 1 mg). Typical workflow: inpatient hematology/oncology admits the patient for conditioning; baseline labs (CBC, CMP, liver function tests), venous access placement and premedication as indicated are completed. Pharmacy compounds the busulfan dose per weight-based protocol, and the infusion is administered by oncology nursing in an inpatient infusion suite or bone marrow transplant unit. Therapeutic drug monitoring for busulfan plasma levels is performed to adjust dosing on subsequent doses. Nursing documents administration, any infusion-related reactions, and supportive care (anticonvulsant prophylaxis if indicated). Billing is submitted using J0594 with appropriate patient-specific modifiers reflecting the service conditions (for example, JW for wasted drug portions).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug wastage discarded | When a portion of a dispensed busulfan vial is discarded and must be reported for discarded amount billing compliance. |